Home/Filings/4/0001209191-22-015809
4//SEC Filing

Ruffo Frank 4

Accession 0001209191-22-015809

CIK 0001557746other

Filed

Mar 2, 7:00 PM ET

Accepted

Mar 3, 6:08 PM ET

Size

20.0 KB

Accession

0001209191-22-015809

Insider Transaction Report

Form 4
Period: 2022-03-01
Ruffo Frank
Chief Financial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2022-03-01+8,300206,409 total
  • Exercise/Conversion

    Common Stock

    2022-03-02+8,297214,706 total
  • Award

    Restricted stock units

    2022-03-01+44,30044,300 total
    Common Stock (44,300 underlying)
  • Exercise/Conversion

    Restricted stock units

    2022-03-0125,75025,750 total
    Common Stock (25,750 underlying)
  • Exercise/Conversion

    Restricted stock units

    2022-03-028,29716,595 total
    Common Stock (8,297 underlying)
  • Award

    Employee Stock Option (Right to Buy)

    2022-03-01+155,200155,200 total
    Exercise: $14.94Exp: 2032-02-29Common Stock (155,200 underlying)
  • Exercise/Conversion

    Common Stock

    2022-03-01+25,750198,109 total
  • Exercise/Conversion

    Restricted stock units

    2022-03-018,30024,900 total
    Common Stock (8,300 underlying)
Footnotes (6)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
  • [F2]Exercisable with respect to 25% of the shares subject to the option vesting in four equal annual installments beginning on March 1, 2023, subject to Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date.
  • [F3]The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date.
  • [F4]The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.
  • [F5]The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.
  • [F6]The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

Issuer

Aclaris Therapeutics, Inc.

CIK 0001557746

Entity typeother

Related Parties

1
  • filerCIK 0001654450

Filing Metadata

Form type
4
Filed
Mar 2, 7:00 PM ET
Accepted
Mar 3, 6:08 PM ET
Size
20.0 KB